DBV Technologies Receives FDA Feedback On Design Elements For Viaskin Peanut Safety Studies; Expects To Seek Final Alignment With FDA On COMFORT Protocols Prior To Commencing Studies
Portfolio Pulse from Benzinga Newsdesk
DBV Technologies has received feedback from the U.S. Food and Drug Administration (FDA) on its two supplemental safety studies for Viaskin Peanut in toddlers and children. The company plans to seek final alignment with the FDA on the COMFORT protocols before starting the studies. DBV closed Q2 2023 with a cash balance of $174 million.
July 31, 2023 | 8:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DBV Technologies' stock may be impacted by the FDA feedback on its Viaskin Peanut safety studies. The company's financial health is also highlighted with a Q2 2023 cash balance of $174 million.
The FDA feedback on DBV's safety studies is a crucial step in the development and approval process of Viaskin Peanut. This could potentially lead to a positive impact on the company's stock. The company's strong cash balance also indicates good financial health, which is a positive sign for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100